**Supplementary Table 7** Comparison of the sensitivity of the aMAP-CT model with other existing HCC risk scores in predicting HCC development among each cohort.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Model** | **LSM-HCC** | **CU-HCC** | **PAGE-B** | **mPAGE-B** | **THRI** |
| Training Cohort | 0.458\* | 0.125\* | 0.458\* | 0.625\* | 0.625\* |
| Validation Cohort | 0.545\* | 0.273 | 0.909\* | 0.818\* | 0.727\* |
| Test Cohort | 0.446\* | 0.193\* | 0·675\* | 0.614\* | 0.651\* |
| **Model** | **aMAP** | **aMAP-2** | **aMAP-2 plus****(18 months) a** | **aMAP-CT****(18 months) b** | **aMAP-CT** |
| Training Cohort | 0.542\* | 0.750\* | 0.929 # | 0.857 | 0.792 |
| Validation Cohort | 0.636\* | 0.636 | 0.286 | 0.714 | 0.727 |
| Test Cohort | 0.506\* | 0.614\* | 0.786 # | 0.857 | 0.602 |

**a**: cfDNA signatures were only available within the first 12 months after enrollment in PreCar cohort, thus the performance of aMAP-2 Plus score was evaluated for HCC risk within 18 months.

**b**: In comparison with aMAP-2 plus, aMAP-CT was assessed for HCC risk at the same 18-month time.

\* *p value* (vs. aMAP-CT score) <0.0001 (McNemar test).

# *p value* (vs. aMAP-CT score) > 0.01 (McNemar test).